Skip to main content
SpringerLink
Log in

Oxidative Stress in the Development of Alzheimer’s Disease and Other Dementias

  • Chapter
Alzheimer’s Disease

Part of the book series: Current Clinical Neurology ((CCNEU))

  • 351 Accesses

Abstract

Alzheimer’s disease (AD) is the most common, complex, and challenging form of neurodegenerative disease associated with dementia in the elderly. As people live to older ages, AD is becoming a major medical and social concern. It affects approximately 4 million individuals in the United States and 16 million worldwide, with an incidence that doubles every 5 years, beyond the age of 65 (1,2). A search of the National Institutes of Health database (Medline/PubMed) in December 2002 using the term “Alzheimer’s disease” produced 34,800 citations. This finding clearly indicates the enormous amount of basic science, animal, and human research that has been devoted in recent years to the understanding of this devastating disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clark, C.M.: Clinical manifestations and diagnostic evaluation of patients with Alzheimer s disease. In: Clark, C.M.; Trojanowski, J.Q. (eds.): Neurodegenerative dementias: clinical features and pathological mechanisms. McGraw-Hill, New York, 2000: 95–114.

    Google Scholar 

  2. Zabar, Y.; Kawas, C.H.: Epidemiology and clinical genetics of Alzheimer’s disease. In: Clark, C.M.; Trojanowski, J.Q. (eds.): Neurodegenerative dementias: clinical features and pathological mechanisms. McGraw-Hill, New York, 2000: 79–94.

    Google Scholar 

  3. Khachaturian, Z.S.: Diagnosis of Alzheimer’s disease. Arch Neurol 1985; 42: 1097–1105.

    Article  PubMed  CAS  Google Scholar 

  4. Praticò, D.; Trojanowski, J.Q.: Inflammatory hypotheses: novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? Neurobiol Aging 2000; 21: 441–445.

    Article  PubMed  Google Scholar 

  5. Praticò, D.; Delanty, N.: Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–585.

    Article  PubMed  Google Scholar 

  6. Floyd, R.A.: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 1999; 222: 236–245.

    Article  PubMed  CAS  Google Scholar 

  7. Praticò, D.: Alzheimer’s disease and oxygen radicals: new insights. Biochem Pharmacol 2002; 63: 563–567.

    Article  PubMed  Google Scholar 

  8. Smith, M.A. et al.: Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000; 1502: 139–144.

    Article  PubMed  CAS  Google Scholar 

  9. Christen, Y.: Oxidative stress and Alzheimer’s disease. Am J Clin Nutr 2000; 71: 621S - 629S.

    PubMed  CAS  Google Scholar 

  10. Halliwell, B.; Chirico, S.: Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57: 7155–7255.

    Google Scholar 

  11. Halliwell, B.; Gutteridge, J.M.C.: Free radicals in biology and medicine, 3rd ed. Oxford University Press, Oxford, 1999.

    Google Scholar 

  12. Praticò, D.: Lipid peroxidation and the aging process. SAGE KE 50/re5, 2002.

    Google Scholar 

  13. Praticò, D.: F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1–10.

    Article  PubMed  Google Scholar 

  14. Praticò, D. et al.: The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12: 243–247.

    Article  PubMed  Google Scholar 

  15. Morrow, J.D. et al.: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sc USA 1990; 87: 9383–9387.

    Article  CAS  Google Scholar 

  16. Praticò, D.; Lawson, J.A.; FitzGerald, G.A.: Cyclooxygenase-dependent formation of the isoprostane 8-epi PGF2. J Biol Chem 1995; 270: 9800–9808.

    Article  PubMed  Google Scholar 

  17. Praticò, D. et al.: IPF2,„- I: a novel index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998; 95: 3449–3454.

    Article  PubMed  Google Scholar 

  18. Lawson, J.A. et al: Identification of two major F2 isoprostanes, 8,12-iso and 5-epi-8,12-iso-isoprostane F2-VI, in human urine. J Biol Chem 1998; 273: 29295–29301.

    Article  PubMed  CAS  Google Scholar 

  19. Subbarao, K.V.; Richardson, J.S.; Ang, L.C.: Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro. J Neurochem 1990; 55: 342–345.

    Article  PubMed  CAS  Google Scholar 

  20. Balazs, L.; Leon, M.: Evidence of an oxidative challenge in the Alzheimer’s brain. Neurochem Res 1994; 19: 1131–1137.

    Article  PubMed  CAS  Google Scholar 

  21. Lovell, M.A. et al.: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995; 45: 1594–1601.

    Article  PubMed  CAS  Google Scholar 

  22. Jeandel, C. et al.: Lipid peroxidation and free radical scavengers in Alzheimer’s disease. Gerontology 1989; 35: 275–282.

    Article  PubMed  CAS  Google Scholar 

  23. Bourdel-Marchyasson, I. et al.: Antioxidant defenses and oxidative markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001; 30: 235–241.

    Article  Google Scholar 

  24. Markesbery, W.R.; Lovell, M.A.: Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging 1998; 19: 33–36.

    Article  PubMed  CAS  Google Scholar 

  25. Lovell, M.A. et al.: Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging 1997; 18: 457–461.

    Article  PubMed  CAS  Google Scholar 

  26. Praticò, D. et al.: Increased F2-isoprostanes in Alzheimer’s disease: evidence of enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 177–178.

    Google Scholar 

  27. Praticò, D. et al.: Increased 8,12-iso-iPF2„- VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809–812.

    Article  PubMed  Google Scholar 

  28. Tuppo, E.E. et al.: Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer’s disease. Brain Res Bull 2001; 54: 565–568.

    Article  PubMed  CAS  Google Scholar 

  29. Coyle, J.T. et al.: The neurobiologic consequences of Down’s syndrome. Brain Res Bull 1986; 16: 773–787.

    Article  PubMed  CAS  Google Scholar 

  30. Praticò, D. et al.: Down’s syndrome is associated with increased 8,12-iso-iPF2-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000; 48: 795–798.

    Article  PubMed  Google Scholar 

  31. Petersen, R.C.: Normal aging, mild cognitive impairment, and early Alzheimer’s disease. Neurologist 1995; 1: 326–344.

    Google Scholar 

  32. Praticò, D. et al.: Increase of oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer’s disease. Arch Neurol 2002; 59: 972–976.

    Article  PubMed  Google Scholar 

  33. Andreasen, N. et al.: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer’s disease. Arch Neurol 2001; 58: 373–379.

    Article  PubMed  CAS  Google Scholar 

  34. McKhann, G.M. et al.: Clinical and pathological diagnosis of frontotemporal dementia: report of work group on frontotemporal dementia and Pick’s disease. Ann Neurol 2001; 58: 1803–1809.

    CAS  Google Scholar 

  35. Knopman, D.S.: Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 1993; 4: 132–136.

    PubMed  CAS  Google Scholar 

  36. Giannakopoulos, P.; Holf, P.R.; Bouras, C.: Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 1995; 89: 346–355.

    Article  PubMed  CAS  Google Scholar 

  37. Mann, D.A. et al.: Dementia of the frontal lobe type-neuropathology and immunohistochemistry. J Neurol Neurosurg Psychiatry 1993; 56: 605–614.

    Article  PubMed  CAS  Google Scholar 

  38. Arnold, S.E.: Cellular and molecular pathology of the frontal dementias. In: Clark, C.V.M.; Trojanowski, J.Q. (eds.): Neurodegenerative dementias: clinical features and pathological mechanisms. McGraw-Hill, New York, 2000: 291–301.

    Google Scholar 

  39. Castellani, R.J. et al.: Evidence for oxidative stress in Pick’s disease and corticobasal dgeneration. Brain Res 1995; 696: 268–271.

    Article  PubMed  CAS  Google Scholar 

  40. Gerst, J.L. et al.: Role of oxidative stress in frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 (S): 85–87.

    Article  PubMed  CAS  Google Scholar 

  41. Albers, D.S. et al.: Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 1997; 73: 881–884.

    Article  Google Scholar 

  42. Albers, D.S. et al.: Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 2000; 72: 878–881.

    Google Scholar 

  43. Odetti, P. et al.: Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000; 59: 393–397.

    PubMed  CAS  Google Scholar 

  44. Montine, K.S. et al.: 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997; 56: 866–871.

    Article  PubMed  CAS  Google Scholar 

  45. Clark, C.M. et al.: A urine measure of oxidative damage distinguishes patients with frontotemporal dementia from those with Alzheimer’s disease. Neurobiol Aging 2003; 23: S234.

    Google Scholar 

Download references

Authors
  1. Domenico Praticò
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Oklahoma College of Medicine, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  2. Alzheimer’s Disease Research Unit, St. John Medical Center, Tulsa, OK, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  3. Tulsa, OK, USA

    Brigitte Zoeller Richter DiplPharm (Pharmacist, Publicist) (Pharmacist, Publicist)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Praticò, D. (2004). Oxidative Stress in the Development of Alzheimer’s Disease and Other Dementias. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-661-4_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4485-9

  • Online ISBN: 978-1-59259-661-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation